Acquired capabilities Alligent Group is now part of Envision Pharma Group, indicating potential access to expanded resources, cross-sell opportunities across integrated medical affairs services, and a broader client base within a technology-enabled life sciences platform.

Integrated offerings The company provides end-to-end medical affairs support from strategy to execution, including clinical trial design, data explorations, trial management, publications, scientific communication, and training, creating multiple touchpoints for upsell in research, publications, and medical communications services.

Tech-forward Adoption of diverse tech stack (Qlik, MongoDB, Figma, Spring Boot, HubSpot) suggests readiness for data-driven insights, streamlined content development, and robust CRM marketing and sales enablement potential to offer clients analytics, automation, and visualization services.

Leadership momentum Recent executive hires across leadership roles in operations, technology, and people indicate strategic growth and renewed focus, signaling a strong window for enterprise partnerships and larger contract opportunities with upgraded governance and service capabilities.

Funding and scale signals Revenue range positioned between 10M and 25M with a small to mid-sized employee base suggests opportunities to target mid-market pharmaceutical and biotech clients seeking scalable, cost-effective medical affairs outsourcing and digital solutions aligned with Envision’s platform.